(SAN) Sanofi - Overview
Stock: Vaccines, Immunology, Neurology, Oncology, Rare Diseases
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.30% |
| Yield on Cost 5y | 6.11% |
| Yield CAGR 5y | 5.34% |
| Payout Consistency | 99.7% |
| Payout Ratio | 96.8% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.7% |
| Relative Tail Risk | -7.29% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.90 |
| Alpha | -22.47 |
| Character TTM | |
|---|---|
| Beta | -0.090 |
| Beta Downside | -0.017 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.59% |
| CAGR/Max DD | -0.01 |
Description: SAN Sanofi January 27, 2026
Sanofi (PA:SAN) is a global integrated healthcare company that discovers, develops, manufactures, and markets therapeutic solutions across several therapeutic areas, including immunology & inflammation, rare diseases, neurology, oncology, and vaccines. Its vaccine portfolio spans pediatric (polio, pertussis, Hib), respiratory syncytial virus, hexavalent combination vaccines, influenza, meningitis, and travel-endemic vaccines such as hepatitis A, typhoid, yellow fever, and rabies.
The firm maintains an extensive external innovation network. Notable agreements include a partnership with Exscientia to co-develop up to 15 novel small-molecule candidates for oncology and immunology, collaborations with ABL Bio (ABL301 for α-synucleinopathies), Innate Pharma (NK-cell engager targeting B7-H3), Blackstone Life Sciences (pivotal clinical programs), IGM Biosciences (IgM antibodies), Kymera Therapeutics (IRAK4 degraders), Nurix Therapeutics (targeted protein degradation), Denali Therapeutics (systemic inflammatory diseases), Adagene (antibody discovery), Scribe Therapeutics (genome editing), and a co-promotion deal with Provention Bio for teplizumab. A strategic alliance with Abu Dhabi’s Department of Health supports global vaccine development.
Key recent metrics (2023-2024):
• 2023 total revenue of €42.1 bn, with vaccines contributing €9.3 bn (+12% YoY, driven by COVID-19 booster demand).
• R&D expenditure reached €5.9 bn, representing 14% of sales and supporting a pipeline of 12 oncology candidates and 8 late-stage immunology projects.
• Sanofi’s immunology franchise grew 8% YoY, reflecting strong uptake of its IL-23 inhibitor Dupixent in the U.S. market.
These figures suggest that vaccine sales remain a growth engine, while the company’s heavy R&D spend is aimed at diversifying revenue beyond mature products. However, the success of early-stage collaborations (e.g., Exscientia’s AI-driven molecules) carries high uncertainty and will materially affect future earnings.
For a deeper, data-driven assessment of Sanofi’s valuation drivers and scenario analysis, you may find the ValueRay platform useful.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 7.81b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 6.08 > 1.0 |
| NWC/Revenue: 5.98% < 20% (prev 29.53%; Δ -23.55% < -1%) |
| CFO/TA 0.13 > 3% & CFO 17.06b > Net Income 7.81b |
| Net Debt (14.14b) to EBITDA (11.07b): 1.28 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (523.5m) vs 12m ago -58.24% < -2% |
| Gross Margin: 70.09% > 18% (prev 0.70%; Δ 6939 % > 0.5%) |
| Asset Turnover: 33.61% > 50% (prev 34.24%; Δ -0.63% > 0%) |
| Interest Coverage Ratio: 13.98 > 6 (EBITDA TTM 11.07b / Interest Expense TTM 563.0m) |
Beneish M -3.85
| DSRI: 0.04 (Receivables 397.0m/10.63b, Revenue 43.63b/45.47b) |
| GMI: 1.00 (GM 70.09% / 70.04%) |
| AQI: 1.12 (AQ_t 0.67 / AQ_t-1 0.59) |
| SGI: 0.96 (Revenue 43.63b / 45.47b) |
| TATA: -0.07 (NI 7.81b - CFO 17.06b) / TA 126.81b) |
| Beneish M-Score: -3.85 (Cap -4..+1) = AAA |
What is the price of SAN shares?
Over the past week, the price has changed by -0.85%, over one month by -3.79%, over three months by -8.90% and over the past year by -20.84%.
Is SAN a buy, sell or hold?
What are the forecasts/targets for the SAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 100 | 26.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 75.9 | -4.2% |
SAN Fundamental Data Overview February 01, 2026
P/E Trailing = 19.5556
P/E Forward = 9.1324
P/S = 2.0537
P/B = 1.3042
P/EG = 0.6815
Revenue TTM = 43.63b EUR
EBIT TTM = 7.87b EUR
EBITDA TTM = 11.07b EUR
Long Term Debt = 11.70b EUR (from longTermDebt, two quarters ago)
Short Term Debt = 4.61b EUR (from shortTermDebt, last quarter)
Debt = 21.80b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.14b EUR (from netDebt column, last quarter)
Enterprise Value = 110.08b EUR (95.94b + Debt 21.80b - CCE 7.66b)
Interest Coverage Ratio = 13.98 (Ebit TTM 7.87b / Interest Expense TTM 563.0m)
EV/FCF = 6.40x (Enterprise Value 110.08b / FCF TTM 17.21b)
FCF Yield = 15.63% (FCF TTM 17.21b / Enterprise Value 110.08b)
FCF Margin = 39.45% (FCF TTM 17.21b / Revenue TTM 43.63b)
Net Margin = 17.91% (Net Income TTM 7.81b / Revenue TTM 43.63b)
Gross Margin = 70.09% ((Revenue TTM 43.63b - Cost of Revenue TTM 13.05b) / Revenue TTM)
Gross Margin QoQ = 58.79% (prev 74.09%)
Tobins Q-Ratio = 0.87 (Enterprise Value 110.08b / Total Assets 126.81b)
Interest Expense / Debt = -0.43% (Interest Expense -93.0m / Debt 21.80b)
Taxrate = 17.33% (1.04b / 6.02b)
NOPAT = 6.51b (EBIT 7.87b * (1 - 17.33%))
Current Ratio = 1.09 (Total Current Assets 30.95b / Total Current Liabilities 28.35b)
Debt / Equity = 0.31 (Debt 21.80b / totalStockholderEquity, last quarter 71.38b)
Debt / EBITDA = 1.28 (Net Debt 14.14b / EBITDA 11.07b)
Debt / FCF = 0.82 (Net Debt 14.14b / FCF TTM 17.21b)
Total Stockholder Equity = 72.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.02% (Net Income 7.81b / Total Assets 126.81b)
RoE = 10.82% (Net Income TTM 7.81b / Total Stockholder Equity 72.18b)
RoCE = 9.38% (EBIT 7.87b / Capital Employed (Equity 72.18b + L.T.Debt 11.70b))
RoIC = 7.05% (NOPAT 6.51b / Invested Capital 92.30b)
WACC = 4.48% (E(95.94b)/V(117.74b) * Re(5.58%) + D(21.80b)/V(117.74b) * Rd(-0.43%) * (1-Tc(0.17)))
Discount Rate = 5.58% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -35.38%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈14.30b ; Y1≈17.64b ; Y5≈30.05b
Fair Price DCF = 712.9 (EV 875.04b - Net Debt 14.14b = Equity 860.90b / Shares 1.21b; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -22.25 | EPS CAGR: -6.13% | SUE: 0.40 | # QB: 0
Revenue Correlation: -2.34 | Revenue CAGR: -2.58% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.71 | Chg30d=+0.050 | Revisions Net=+2 | Analysts=3
EPS current Year (2026-12-31): EPS=8.36 | Chg30d=-0.046 | Revisions Net=+3 | Growth EPS=+6.8% | Growth Revenue=+6.9%
EPS next Year (2027-12-31): EPS=8.94 | Chg30d=-0.054 | Revisions Net=+0 | Growth EPS=+7.0% | Growth Revenue=+6.1%